Thank you to our 2022 PEDS attendees!
Please stay tuned for details about the 2023 Pediatric Early Development Symposium.
In the meantime, we invite you to review the 2022 PEDS Impact Report below.
What is PEDS?
Launched in 2020 in response to the passage of Title V of the FDA Reauthorization Act, commonly known as the RACE for Children Act, the CureSearch Pediatric Early Development Symposium (PEDS) serves as an opportunity for industry, academia and regulatory leaders to examine the dynamic nature of clinical trials for a super rare population - children with cancer.
Each subsequent PEDS has built upon the last, returning participants to a mindset of advancing pediatric cancer clinical trials and exploring resources, infrastructure, collaborations and – in 2022 – technological integrations that make clinical trials for rare patient populations more robust and efficient. Register to join us here.
Symposium Co-Chairs
Jeffrey Skolnik, MD
Vice President,
Clinical Development
INOVIO Pharmaceuticals
Brenda Weigel, MD
Director of the Division of
Pediatric Hematology/Oncology,
University of Minnesota's Masonic Cancer Center
Working Group Members
Attendees
Industry leaders, academics and other thought leaders in pediatric drug development.
- Medical Affairs
- Clinical Affairs
- Project Management
- Regulatory Affairs
- Research and Development
- Early Development
- Late Development
- Clinical Operations
- Executives
- Management
- Academic
- Patient Advocates
- Regulators
- Other key opinion leaders
Our
Sponsors
To learn more about becoming a sponsor for the 2022 Pediatric Early Development Symposium, please contact chris.riley@curesearch.org.